ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) EBIT : kr-83.70 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is ExpreS2ion Biotech Holding AB EBIT?

ExpreS2ion Biotech Holding AB's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was kr-13.68 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-83.70 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ExpreS2ion Biotech Holding AB's annualized ROC % for the quarter that ended in Mar. 2024 was -175.44%. ExpreS2ion Biotech Holding AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -3,109.55%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. ExpreS2ion Biotech Holding AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -903.55%.

ExpreS2ion Biotech Holding AB EBIT Historical Data

The historical data trend for ExpreS2ion Biotech Holding AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ExpreS2ion Biotech Holding AB EBIT Chart

ExpreS2ion Biotech Holding AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-18.67

-31.39

-47.52

-125.71

-99.47

ExpreS2ion Biotech Holding AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-29.97	-33.24	-22.16	-14.62	-13.68

Competitive Comparison of ExpreS2ion Biotech Holding AB's EBIT

For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ExpreS2ion Biotech Holding AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ExpreS2ion Biotech Holding AB's EV-to-EBIT falls into.

ExpreS2ion Biotech Holding AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-83.70 Mil.

ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ExpreS2ion Biotech Holding AB's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-56.7 * ( 1 - 7.12% )	/	( (19.57	+	40.467)	/ 2 )
=	-52.66296	/	30.0185
=	-175.44 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	78.692	-	1.837	-	( 57.597	-	max(0, 11.382	-	68.667	+	57.597	))
=	19.57

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	86.145	-	1.639	-	( 60.203	-	max(0, 31.947	-	75.986	+	60.203	))
=	40.467

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

ExpreS2ion Biotech Holding AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-54.728	/	( ( (1.769 + max(-1.439, 0))	+	(1.751 + max(-20.756, 0)) )	/	2 )
=	-54.728	/	( ( 1.769	+	1.751 )	/	2 )
=	-54.728	/	1.76
=	-3,109.55 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.95	+	0	+	8.718)	-	(1.837	+	0	+	9.27)
=	-1.439

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.402	+	0	+	9.498)	-	(1.639	+	0	+	30.017)
=	-20.756

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

ExpreS2ion Biotech Holding AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-83.696	/	9.263
	=	-903.55 %

ExpreS2ion Biotech Holding AB EBIT Related Terms

Thank you for viewing the detailed overview of ExpreS2ion Biotech Holding AB's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

5JD:Germany

Address

c/o Mindpark, Ronnowsgatan 8c, Helsingborg, SWE, S-252 25

Website

https://www.expres2ionbio.com

ExpreS2ion Biotech Holding AB has developed a technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. The company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with research institutions and companies.

ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Headlines

No Headlines